Physician profile
Sumana Reddy
NPI 1174987416
$3,352.25
in general payments reported to CMS, 2019-2025
21 companies · $389 in 2025
The $389 reported for 2025 was less than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $597 · 2020: $90.42 · 2021: $221 · 2022: $975 · 2023: $672 · 2024: $409 · 2025: $389.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,469.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,469.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $864.66 | 2021-2025 | Tezspire, Fasenra, Airsupra |
| Genzyme Corporation | $520.33 | 2019-2025 | |
| Glaxosmithkline, LLC. | $412.55 | 2020-2025 | Trelegy Ellipta, Nucala |
| Abbvie INC. | $163.19 | 2021-2024 | |
| Regeneron Healthcare Solutions, INC. | $159.01 | 2022-2024 | Dupixent |
| Novartis Pharmaceuticals Corporation | $149.00 | 2023-2025 | |
| Kaleo, INC. | $141.80 | 2021-2023 | Auvi-Q |
| Genentech USA, INC. | $112.49 | 2023-2024 | Xolair |
| Csl Behring | $106.12 | 2020-2025 | Andembry |
| Pfizer INC. | $92.21 | 2021-2024 | |
| Octapharma USA, INC. | $75.25 | 2024 | Panzyga |
| Biocryst US Sales Co., LLC | $71.18 | 2023-2025 | Orladeyo |
| Takeda Pharmaceuticals U.S.A., INC. | $60.62 | 2024-2025 | Takhzyro, Hyqvia |
| Grifols USA, LLC | $55.89 | 2023-2024 | Xembify, Prolastin-C Liquid |
| Teva Pharmaceuticals USA, INC. | $43.39 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $32.17 | 2022-2023 | Tezspire |
| Leo Pharma INC. | $27.79 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.45 | 2021 | |
| Hikma Pharmaceuticals USA | $15.48 | 2023 | Ryaltris |
| Pharming Healthcare, INC. | $14.58 | 2025 | Ruconest |
| Xeris Pharmaceuticals, INC. | $14.19 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sumana Reddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.